Table 1.

Participant Characteristics and Reproductive Endocrine Evaluation

IDa	Sex	At enrollment				Before pituitary priming			After pituitary priming	Follow-up
		Age, y	Pubertal development	LH, mIU/mL	FSH, mIU/mL	Overnight LH pulses	Inhibin B, pg/mL	ΔLHGnRH, mIU/mL	ΔLHkisspeptin,mIU/mL	Pubertal progression?
1	M	17.0	Absent	0.1	0.2	Absent	< 17	0.2	0	N
2	M	15.7	Absent	0.2	0.2	Absent	< 17	0.2	0	N
3	F	16.7	Absent	< 0.2	0.2	Absent	ND	0.5	0	N
4	M	15.6	Absent	0.1	0.7	Absent	< 17	0.6	0	N
A	M	16.4	Absent	< 0.1	0.3	Absent	23	0.7	0	N
5	F	15.2	Absent	0.1	0.5	Absent	ND	0.8	0	Lost to follow-up
6	F	16.5	Absent	< 0.2	0.6	Absent	ND	1.3	0	N
7	M	14.9	Absent	0.1	0.3	Absent	< 17	1.6	0.1	N
8	M	14.6	Absent	0.8	1.4	Absent	47	7.5	0.4	N
9	M	16.0	Stalled	0.1	0.5	Present	209	3.7	0.8	Y
10	M	14.9	Absent	< 0.3	1.1	Present	96	3.0	0.8	Y
B	F	15.0	Absent	0.1	0.2	Absentb	ND	1.2	0.9	Y
11	M	15.1	Stalled	0.1	0.3	Absentb	156	6.3	1.0	Y
12	M	14.8	Absent	0.1	1.7	Present	44	3.1	1.4	Y
13	F	13.9	Absent	0.1	1.0	Present	ND	1.7	1.4	Y
14	M	17.5	Stalled	0.2	0.7	Present	66	15.4	1.5	Y
15	M	14.2	Absent	0.6	3.4	Present	39	2.0	1.7	Y

Abbreviations: ΔLH_kisspeptin, increase in luteinizing hormone (LH) after kisspeptin; ΔLH_GnRH, increase in LH after gonadotropin-releasing hormone (GnRH), F, female; FSH, follicle-stimulating hormone; ID, identification; M, male; N, no; ND, not done; Y, yes.

^aParticipants with numerical IDs are numbered as in Chan et al (20); participants with alphabetical IDs enrolled in the study after that report.

^bParticipants B and 11 were receiving exogenous sex steroids at the time of their prepriming visits. Some data in this table were previously reported in Chan et al (20).